azathioprine has been researched along with Multiple Sclerosis, Chronic Progressive in 9 studies
Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.
Multiple Sclerosis, Chronic Progressive: A form of multiple sclerosis characterized by a progressive deterioration in neurologic function which is in contrast to the more typical relapsing remitting form. If the clinical course is free of distinct remissions, it is referred to as primary progressive multiple sclerosis. When the progressive decline is punctuated by acute exacerbations, it is referred to as progressive relapsing multiple sclerosis. The term secondary progressive multiple sclerosis is used when relapsing remitting multiple sclerosis evolves into the chronic progressive form. (From Ann Neurol 1994;36 Suppl:S73-S79; Adams et al., Principles of Neurology, 6th ed, pp903-914)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Azathioprine (AZA) is a purine analogue which has been used in the treatment of multiple sclerosis (MS) for over 30 years." | 2.46 | [Oral cladribine for relapsing-remitting multiple sclerosis: another purine analogue or a genuine therapeutic innovation?]. ( Schmidt, S, 2010) |
| "Forty-seven patients with secondary progressive multiple sclerosis and seven others with primary progressive received monthly infusions of cyclophosphamide (750mg/m2) and methylprednisolone (500mg)." | 1.32 | [Treatment of progressive multiple sclerosis with monthly pulsed cyclophosphamide-methylprednisolone: predictive factors of treatment response]. ( Bourg, V; Chanalet, S; Chatel, M; Delmont, E; Lebrun, C; Soriani, MH, 2004) |
| " Most clinics use intravenous steroids for treating relapses, although with different dosing regimens." | 1.30 | Current status of multiple sclerosis therapy in Germany: a national survey. ( Berenbeck, C; Buhmann, C; Emskotter, T; Hadji-Abdolrahim, B; Hauer, S; Heesen, C, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 7 (77.78) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schmidt, S | 1 |
| Fernández, O | 1 |
| Guerrero, M | 1 |
| Mayorga, C | 1 |
| Muñoz, L | 1 |
| Leán, A | 1 |
| Luque, G | 1 |
| Hervás, M | 1 |
| Fernández, V | 1 |
| Capdevila, A | 1 |
| de Ramón, E | 1 |
| Kieseier, BC | 1 |
| Hartung, HP | 1 |
| Lacour, A | 1 |
| De Seze, J | 1 |
| Revenco, E | 1 |
| Lebrun, C | 2 |
| Masmoudi, K | 1 |
| Vidry, E | 1 |
| Rumbach, L | 1 |
| Chatel, M | 2 |
| Verier, A | 1 |
| Vermersch, P | 1 |
| Delmont, E | 1 |
| Chanalet, S | 1 |
| Bourg, V | 1 |
| Soriani, MH | 1 |
| La Mantia, L | 1 |
| D'Amico, D | 1 |
| Rigamonti, A | 1 |
| Mascoli, N | 1 |
| Bussone, G | 1 |
| Milanese, C | 1 |
| Yerdelen, D | 1 |
| Karatas, M | 1 |
| Goksel, B | 1 |
| Yildirim, T | 1 |
| Heesen, C | 1 |
| Hauer, S | 1 |
| Hadji-Abdolrahim, B | 1 |
| Berenbeck, C | 1 |
| Buhmann, C | 1 |
| Emskotter, T | 1 |
| Lublin, FD | 1 |
3 reviews available for azathioprine and Multiple Sclerosis, Chronic Progressive
| Article | Year |
|---|---|
[Oral cladribine for relapsing-remitting multiple sclerosis: another purine analogue or a genuine therapeutic innovation?].
Topics: Administration, Oral; Adverse Drug Reaction Reporting Systems; Animals; Azathioprine; Cladribine; Cl | 2010 |
Current disease-modifying therapies in multiple sclerosis.
Topics: Adjuvants, Immunologic; Analgesics; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azath | 2003 |
Therapeutic approaches to secondary progressive multiple sclerosis.
Topics: Anti-Inflammatory Agents; Azathioprine; Bone Marrow Transplantation; Cladribine; Clinical Trials as | 2002 |
1 trial available for azathioprine and Multiple Sclerosis, Chronic Progressive
| Article | Year |
|---|---|
Interferon treatment may trigger primary headaches in multiple sclerosis patients.
Topics: Adjuvants, Immunologic; Adult; Aged; Azathioprine; Female; Glatiramer Acetate; Headache; Humans; Imm | 2006 |
5 other studies available for azathioprine and Multiple Sclerosis, Chronic Progressive
| Article | Year |
|---|---|
Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study.
Topics: Adjuvants, Immunologic; Adult; Azathioprine; Disease Progression; Drug Therapy, Combination; Female; | 2002 |
Acute aphasia in multiple sclerosis: A multicenter study of 22 patients.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents; Aphasia; Azathioprine; Brain; Cohort Studies; Comorb | 2004 |
[Treatment of progressive multiple sclerosis with monthly pulsed cyclophosphamide-methylprednisolone: predictive factors of treatment response].
Topics: Adjuvants, Immunologic; Adult; Azathioprine; Brain; Cyclophosphamide; Demography; Drug Therapy, Comb | 2004 |
A patient with multiple sclerosis presenting with Holmes' tremor.
Topics: Adult; Azathioprine; Brain Stem; Cerebellum; Clonazepam; Extremities; Female; GABA Modulators; Human | 2008 |
Current status of multiple sclerosis therapy in Germany: a national survey.
Topics: Adjuvants, Immunologic; Azathioprine; Data Collection; Germany; Humans; Immunosuppressive Agents; Im | 1999 |